Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 6Phase 1/2 3Phase 3 2Phase NA 1Phase 4 1

Status

Completed 2Unknown 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Solid Tumors 1Recurrence 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Ovarian Neoplasms 1Leukemia 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × Drug Evaluation × Clear all
NCT07532148 2026-04-15

Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Chong Kun Dang Pharmaceutical

Phase 1 Not yet recruiting
24 enrolled
Gynecologic

Ovarian Neoplasms

NCT04500587 2024-09-19

Phase 1 First in Human Study of ZN-d5 as a Single Agent

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 1 Completed
39 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute

NCT05758610 2024-05-08

A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

Shengke Pharmaceuticals (Jiangsu) Limited, China

Phase 1 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Myeloid, Acute

NCT04840784 2023-10-11

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML

Shengke Pharmaceuticals (Jiangsu) Limited, China

Phase 1 Terminated
9 enrolled
Other hematologic neoplasm

Leukemia

NCT04972422 2021-09-05

A Phase 1b Study of ZN-c3 in Chinese Subjects

Zentera Therapeutics HK Limited

Phase 1 Unknown
38 enrolled
Other solid neoplasm

Solid Tumors

NCT03236974 2020-02-06

D6090C00002

AstraZeneca

Phase 1 Completed
49 enrolled
Breast

Postmenopausal Women With ER+ HER2- Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡